|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/6886 | (2018.01) |
| C12Q2600/106 | (2013.01) | ||
| C12Q2600/158 | (2013.01) | ||
| A61K 31/497 | (2013.01) | ||
| C12Q 1/6886 | (2013.01) | ||
| A61P 1/18 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3693476 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20154250.3 |
| Date of filing the European patent application | 2013-02-22 | |
| (97) | Date of publication of the European application | 2020-08-12 |
| (45) | Date of publication and mention of the grant of the patent | 2023-10-18 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201261604290 P | 2012-02-28 | US |
| (72) |
CONG, Feng , US
HAO, Huaixiang , US
HSIEH, Hsin-i , US
LIU, Jun , US
NG, Nicholas , US
JIANG, Xiaomo , US
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
| CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |